62nd ASH Annual Meeting and Exposition: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II

Oral and Poster Abstracts
Poster

Adult, ALL, AML, antibodies, apoptosis, Biological, Leukemia, Animal models, Diseases, drug-drug interaction, neurotoxicity, Non-Biological, Bone Marrow Failure, cell regulation, Combinations, Therapies, Adverse Events, Genetic Disorders, Pediatric, Biological Processes, white blood cells, immune cells, Technology and Procedures, Cell Lineage, cytogenetics, epigenetics, immunotherapy, Xenograft models, Lymphoid Malignancies, Study Population, Clinically relevant, genetic profiling, genomics, Myeloid Malignancies, imaging, immune mechanism, transplantation, TKI, integrative -omics, molecular testing, NGS, microenvironment, molecular interactions, RNA sequencing, pathogenesis, WGS, pathways

1978

AML Cells Alter Bone Homeostasis By Promoting the Formation of Immature Bone and Resorption of Mature Bone That Supports Leukemia Progression

Anudishi Tyagi, Ph.D.¹^*, Bin Yuan²^*, Stanley Ly²^*, Fouad El-Dana, M.D.³^*, Vinitha Mary Kuruvilla, MSc⁴^*, Qi Zhang, PhD⁴^*, Christine B Peterson⁵^*, Xin Zhou, PhD⁶^*, Benoit deCrombrugghe⁶^*, Michael Andreeff, MD, PhD⁷, Marina Konopleva, MD, PhD⁸, Behrang Amini, MD, PhD⁹^* and Venkata Lokesh Battula, PhD²

¹UT MD Anderson Cancer Center, Houston, TX
²Section of Molecular Hematology and Therapy, Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
³Leukemia, UT MD Anderson Cancer Center, Houston, TX
⁴Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Department of Biostatistics, UT MD Anderson Cancer Center, Houston
⁶Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX
⁷Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁸Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX
⁹Department of Diagnostic Radiology, University of Texas M.D. Anderson Cancer Center, Houston, TX

1979

Induced CD25⁺CD127^dim Γδ Tregs in Acute Myeloid Leukemia Suppress the Activity of Normal Αβ T Cells

Shuang Liang^1,2^*, Jiangying Liu¹^*, Haitao Gao¹^*, Ruoyang Liu¹^*, Ning Wu¹^*, Tianhui Dong¹^* and Xiaojun Huang, MD^2,3

¹Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, China
²Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China
³Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematology Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

1980

Safety, Tolerability and Efficacy of Crenolanib Administered Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in Patients with FLT3 Mutant AML

Betul Oran, MD, MS¹, Stefan O. Ciurea, MD², Partow Kebriaei, MD³, Rohtesh S. Mehta, MD, MPH, MS⁴, Uday R. Popat, MD⁴, Chitra Hosing, MD³, Jessica M McCarty, RN³^*, Bridget Hindman, PhD⁵^*, Boo Messahel, MD⁵^* and Richard E. Champlin, MD³

¹Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX
²The University of California, Irvine, Irvine, CA
³Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Arog Pharmaceuticals, Plano, TX

1981

Integration of Hi-C and Nanopore Sequencing for Structural Variant Analysis in AML with a Complex Karyotype: (Chromothripsis)²

Marius-Konstantin Klever^1,2,3^*, Eric Sträng, PhD²^*, Julius Jungnitsch^3,4^*, Uirá Souto Melo^1,3^*, Sara Hetzel⁵^*, Anna Dolnik²^*, Robert Schöpflin^1,3^*, Jens F. Schrezenmeier²^*, Olga Blau^2,6, Jörg Westermann⁷^*, Konstanze Dohner, MD⁸, Hubert Schrezenmeier^9,10, Malte Spielmann^4,11^*, Alexander Meissner, PhD¹²^*, Stefan Mundlos^1,3,6^* and Lars Bullinger, MD^2,6

¹RG Development and Disease, Max Planck Institute for Molecular Genetics, Berlin, Germany
²Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine Berlin, Berlin, Germany
³Institute for Medical Genetics and Human Genetics, Charité University Medicine Berlin, Berlin, Germany
⁴Human Molecular Genomics Group, Max Planck Institute for Molecular Genetics, Berlin, Germany
⁵Department of Genome Regulation, Max Planck Institute For Molecular Genetics, Berlin, Germany
⁶Labor Berlin – Charité Vivantes GmbH, Berlin, Germany
⁷Department of Hematology, Oncology and Tumor Immunology, Charite-Universitaetsmedizin Berlin, Berlin, Germany
⁸Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
⁹Institute of Transfusion Medicine, University of Ulm, Ulm, Germany, and Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, and University Hospital Ulm, Ulm, Germany
¹⁰Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm, Ulm, Germany
¹¹Institut für Humangenetik Lübeck, Universität zu Lübeck, Lübeck, Germany
¹²Department of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany

1982

DCE-MRI for Detection of Acute Myeloid Leukemia Derived Bone Marrow Vascular Dysfunction

Ana Da Silva Gomes, PhD¹^*, Bernard Siow, PhD²^*, Diana Passaro, PhD^1,3^* and Dominique Bonnet, PhD¹

¹Hematopoietic Stem Cell lab, The Francis Crick Institute, London, United Kingdom
²In Vivo Imaging, The Francis Crick Institute, London, United Kingdom
³Leukemia and Niche Dynamics lab, Cochin Institute, Paris, France

1983

Meta-Analysis of Genome-Wide Association Studies of Acute Myeloid Leukemia (AML) Patients Identifies Variants Associated with Risk of 11q23/KMT2A-Translocated and Core-Binding Factor (CBF) AML and Suggests a Role for Transcription Elongation in Leukemogenesis

Christopher J. Walker, PhD¹, Junke Wang, MS²^*, Alyssa I. Clay-Gilmour, PhD³, Krzysztof Mrózek, MD, PhD⁴, Deedra Nicolet, MS⁴^*, Christopher C. Oakes, PhD⁵, Jessica Kohlschmidt, PhD⁶, Bayard L. Powell, MD⁷, Jonathan E. Kolitz, MD⁸, Andrew J Carroll, PhD⁹, Ezgi Karaesmen, PhD¹⁰, Abbas A. Rizvi, PhD, MS²^*, Qianqian Zhu, PhD¹¹^*, Li Yan, PhD¹²^*, Leah Preus, MS²^*, Song Liu, PhD¹²^*, Yiwen Wang², Daniel O. Stram, PhD¹³^*, Loreall Pooler¹⁴^*, Xin Sheng, MS¹³^*, Christopher Haiman¹⁵^*, David Van Den Berg, PhD¹⁶^*, Amy Webb, PhD¹⁷^*, Guy Brock, PhD¹⁷^*, Stephen R. Spellman, MS¹⁸^*, Marcelo C. Pasquini, MD, MS¹⁹, Philip L. McCarthy, MD²⁰, James M. Allan²¹^*, Friedrich Stolzel, MD²²^*, Kenan Onel, MD, PhD²³, Richard M. Stone, MD²⁴, Ramiro Garzon, MD²⁵, Clara D. Bloomfield, MD²⁶, John C. Byrd, MD²⁷, Albert de la Chapelle, MD, PhD¹^*, Theresa E. Hahn, PhD²⁸, Ann-Kathrin Eisfeld, MD²⁷ and Lara E. Sucheston-Campbell, PhD, MS²⁹

¹The Ohio State University, Comprehensive Cancer Center, Columbus, OH
²College of Pharmacy, The Ohio State University, Columbus, OH
³Arnold School of Public Health- Department of Epidemiology & Biostatistics, University of South Carolina, Greenville, SC
⁴The Ohio State University Comprehensive Cancer Center, Columbus, OH
⁵OSU, Columbus, OH
⁶Alliance Statistics and Data Center, The Ohio State University Comprehensive Cancer Center, Columbus, OH
⁷Wake Forest Univ. School of Med., Winston Salem, NC
⁸Northwell Health Cancer Institute, Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY
⁹Department of Genetics, University of Alabama at Birmingham, Birmingham, AL
¹⁰The Ohio State University, Columbus, OH
¹¹Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY
¹²Department of Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, NY
¹³University of Southern California, Keck School of Medicine of USC, Los Angeles, CA
¹⁴University of Southern California, Los Angeles, CA
¹⁵Keck School of Medicine, Los Angeles, CA
¹⁶Preventive Medicine, University of Southern California, Keck School of Medicine of USC, Los Angeles, CA
¹⁷Department of Biomedical Informatics, The Ohio State University, Columbus, OH
¹⁸CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI
¹⁹Froedtert & The Medical College Cancer Ctr., Milwaukee, WI
²⁰Roswell Park Cancer Institute, Buffalo, NY
²¹Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
²²Department of Hematology and Oncology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany
²³Icahn School of Medicine at Mount Sinai, New York, NY
²⁴Dana-Farber Cancer Institute, Boston, MA
²⁵Ohio State University, Columbus, OH
²⁶Comprehensive Cancer Center, The Ohio State University, Columbus, OH
²⁷Division of Hematology, The Ohio State University, Columbus, OH
²⁸Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
²⁹College of Veterinary Medicine, Cancer Prevention & Control, Columbus, OH

1984

GADD45a Controls Self-Renewal in Acute Myeloid Leukemia Stem Cells

Nunki Hassan, PhD^*, Hangyu Yi, PhD^*, Lucie Gaspard-Boulinc^*, Franklin Chen^*, Jayvee Datuin^*, Jonason Yang^* and Jenny Yingzi Wang, PhD

Children's Cancer Institute, Randwick, NSW, Australia

1985

Duplex Sequencing with Patient-Specific Hybrid Capture Panels Reveals Ultra-Low Frequency Measurable Residual Disease in Pediatric Acute Myeloid Leukemia

Jacob Higgins, PhD¹^*, Fang Yin Lo, PhD¹^*, Michael J. Hipp, MS¹^*, Charles C. Valentine, MS¹^*, Lindsey N. Williams, PhD¹^*, Amanda R. Leonti, MS²^*, Rhonda E. Ries, MA³^*, Jerald P. Radich, MD³, Soheil Meshinchi, MD, PhD³, Benjamin J. Huang, MD⁴^* and Jesse J. Salk, MD, PhD¹

¹TwinStrand Biosciences, Seattle, WA
²Clinical Research Division, Fred Hutchinson Cancer Research Center, Mountlake Terrace, WA
³Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
⁴Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

1986

Mechanisms of Leukemia Stem Cell Plasticity Revealed By Single Cell Analysis

R. Grant Rowe, MD, PhD¹^*, George Q. Daley, MD, PhD², Trista E. North, PhD¹, William Marion¹^*, Yana Pikman, MD³, Marian H. Harris, MD, PhD⁴^*, Vivian Morris¹^*, Edroaldo Lummertz da rocha, PhD⁵^*, Alex K. Shalek, PhD⁶^*, Travis Hughes⁶^*, Prerana Sensharma¹^*, Dahai Wang¹^*, Patricia Sousa²^*, Shannan Ho Sui⁷^*, Sergey Naumenko⁷^* and Renan Vinicius Da Silva⁸^*

¹Boston Children's Hospital, Boston, MA
²Division of Hematology/Oncology, Stem Cell Program, Boston Children's Hospital, Boston, MA
³Dana Farber Cancer Institute, Boston, MA
⁴Department of Pathology, Boston Children's Hospital, Boston, MA
⁵Federal University of Santa Catarina, Florianopolis, Brazil
⁶Massachusetts Institute of Technology, Cambridge, MA
⁷Harvard School of Public Health, Boston, MA
⁸Feseral University of Santa Catarina, Florianopolis, BRA

1987

Methscore As a New Prognostic Tool for Complex DNA Methylation Changes Assessment in Patients with Acute Myeloid Leukemia

Sarka Sestakova^1,2^*, Cyril Šálek, MD^2,3^*, Dávid Kundrát³^*, Ivana Ježíšková⁴^*, Jiří Mayer⁴, Zdeněk Ráčil³^*, Petr Cetkovský³^* and Hana Remešová³^*

¹Institute of Hematology and Blood Transfusion, Praha 2, Czech Republic
²Institute of Clinical and Experimental Hematology, First Faculty of Medicine, Charles University and Institute of Hematology and Blood Transfusion, Prague, Czech Republic
³Institute of Hematology and Blood Transfusion, Prague, Czech Republic
⁴Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

1988

Pretreatment Next-Generation Sequencing Is Associated with Response to Induction Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

Anastasia Tsagianni, MD¹, Konstantinos Lontos, MD², Mounzer Agha, MD², Anastasios Raptis, MD², Jing-Zhou Hou, MD, PhD², Rafic J. Farah, MD², Robert L. Redner, MD², Annie Im, MD², Kathleen A. Dorritie, MD², Alison R. Sehgal, MD², James M. Rossetti, DO², Melissa Saul, MS³^*, William Gooding, MS⁴^* and Michael Boyiadzis, MD²

¹University of Pittsburgh Medical Center, Pittsburgh, PA
²UPMC Hillman Cancer Center, Pittsburgh, PA
³Department of Medicine, University of Pittsburgh, Pittsburgh, PA
⁴UPMC Hillman Cancer Center, Biostatistics Facility, Pittsburgh, PA

1989

Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA

Tracy Murphy, MD, FRCP, FRCPath¹, Stanley W.K. Ng, PhD¹^*, Ian King, PhD²^*, Tong Zhang²^*, Andrea Arruda, MSc¹^*, Narmin Ibrahimova¹^*, Jaime O. Claudio, PhD¹^*, Fiona Ferrera¹^*, Kristele Pan³^*, Chantal Rockwell⁴^*, Zhibin Lu⁵^*, Natalie Stickle⁵^*, Carl Virtanen, MSc⁵^*, Vikas Gupta, MD, FRCP, FRCPath⁶, Dawn Maze, MD, FRCPC, MSc¹, Caroline J McNamara, MBBS⁶, Aaron D Schimmer, MD, PhD¹, Andre C. Schuh¹, Hassan Sibai, MBBS¹^*, Karen W.L. Yee, MD⁶, Dina Khalaf, BSc, MSc, MD⁷, Brian Leber, MD⁷, Mitchell Sabloff, MSc, MD, FRCPC⁴, Anne Tierens, MD, PhD², Mark D. Minden¹, Tracy L. Stockley, PhD, FCCMG, FACMG²^*, Steven M Chan, MD, PhD¹ and Jean C.Y. Wang, MD¹

¹Princess Margaret Cancer Centre, Division of Medical Oncology and Hematology, University Health Network, University of Toronto, Toronto, ON, Canada
²Laboratory Medicine Program, University Health Network, University of Toronto, Toronto, ON, Canada
³Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, ON, Canada
⁴Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada
⁵University Health Network, University of Toronto, Toronto, Canada
⁶Leukemia Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
⁷Division of Hematology, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada

1990

Genomic Landscape of Splicing Factor Mutant Acute Myeloid Leukemia

Hassan Awada, MD¹, Arda Durmaz²^*, Cassandra M. Kerr, MS³^*, Jaroslaw P. Maciejewski, MD, PhD³ and Valeria Visconte, PhD¹

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
²Department of Systems biology and Bioinformatics, CWRU, cleveland
³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

1991

Baseline Mutations Lack Impact on Clinical Outcomes and Molecular Response in Core Binding Factor Leukemia Treated with Highly Effective Regimen

Gautam Borthakur, MD¹, Tapan M. Kadia, MD¹, Guillermo Garcia-Manero, MD¹, Naveen Pemmaraju, MD², Naval Daver, MD¹, Courtney D. DiNardo, MD, MSc¹, Koichi Takahashi, MD, PhD³, Elias Jabbour, MD⁴, Maro Ohanian, DO²^*, Guillermo Montalban Bravo, MD⁵, Farhad Ravandi, MBBS⁶, Hagop M. Kantarjian, MD⁷, Keyur P. Patel, MBBS, PhD⁸ and Mark Brandt, BS¹^*

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX
³Department of Leukemia, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX
⁴Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
⁵The University of Texas MD Anderson Cancer Center, Houston, TX
⁶MD Anderson - University of Texas, Houston, TX
⁷Department of Leukemia, Professor and Chairman, Department of Leukemia, Samsung Distinguished University Chair in Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
⁸Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

1992

High EVI1 Expression Predict Adverse Outcome in Children with Acute Myeloid Leukemia: A Multicenter, Nonrandomized Clinical Study in China

Yongzhi Zheng, MD¹^*, Jian Li, MD¹^*, Xiaoqin Feng²^*, Chunfu Li, MD³, Mincui Zheng⁴^*, Honggui Xu⁵^*, Yingyi He, M.D & Ph.D⁶^*, Xiangling He⁷^* and Jianda Hu, PhD¹

¹Department of Hematology, Fujian Medical University Union Hospital，Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fuzhou, China
²Department of Pediatrics, Nanfang Hospital,Southern Medical University, Guangzhou, China
³Nanfang-Chunfu Children's Institute of Hematology & Oncology, Taixin Hospital, Dongguan, China
⁴Hematology and Oncology, Hunan Children's Hospital, Changsha, China
⁵Sun Yat-sen Memorial Hospital, Guangzhou, China
⁶Department of Pediatric Hematology/Oncology, Guangzhou Women and Children’s Medical Center, Guangzhou, China
⁷Pediatrics, People's Hospital of Hunan Province, Changsha, China

1993

Mesothelin Expression Is Associated with Extramedullary Disease and Promotes In Vivo Leukemic Growth in Acute Myeloid Leukemia

Katherine Tarlock, MD^1,2, Todd A. Alonzo, PhD^3,4^*, Robert B. Gerbing, MA³^*, Quy Le, PhD²^*, Thao T. Tang²^*, Darcy Hamill, DO⁵^*, Anilkumar Gopalakrishnapillai, PhD⁶, Sonali Barwe, PhD, MSc⁷, Rhonda E. Ries, MA²^*, Richard Aplenc, MD, PhD⁸, Andrew C. Wood, MD⁹, E. Anders Kolb, MD¹⁰ and Soheil Meshinchi, MD, PhD¹¹

¹Division of Hematology and Oncology, Seattle Children's Hospital, Seattle, WA
²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
³Children's Oncology Group, Monrovia, CA
⁴University of Southern California, Los Angeles, CA
⁵Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE
⁶Nemours, Wilmington, DE
⁷Alfred I. duPont Hospital for Children, Wilmington, DE
⁸Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA
⁹University of Auckland, Auckland, New Zealand
¹⁰Center for Cancer and Blood Disorders, Nemours Alfred I. duPont Hospital for Children, Wilmington, DE
¹¹Clinical Research Division, Fred Hutchinson Cancer Rsrch. Ctr., Seattle, WA

1994

IDH Mutations Identify a Subgroup of NPM1 Patients with a More Favorable Prognosis. a Retrospective Multicenter Study of the Filo Group

Sylvain Garciaz¹^*, Marie Anne Hospital²^*, Colombe Saillard, MD³^*, Yosr Hicheri⁴^*, Evelyne D'Incan²^*, Jerome Rey²^*, Catherine Lacombe⁵^*, Arnaud Pigneux, MD, PhD⁶^*, Marie-Christine Béné, PharmSciD, PhD⁷^*, Christian Recher, MD, PhD⁸, Marie-Joelle Mozziconacci⁹^* and Norbert Vey, MD¹⁰

¹Institut Paoli Calmettes, Institut Paoli-Calmettes, Marseille, France
²Onco-Hematology Department, Paoli-Calmette Cancer Institute, Marseille, France
³Institut Paoli Calmettes, Marseille, France
⁴Institut Paoli-Calmettes, MARSEILLE, France
⁵INSERM - Institut Cochin Hospital Cochin, Paris, FRA
⁶Hematology Clinic, Bordeaux University Hospital, Pessac, France
⁷Hematology laboratory, CHU, nantes, France
⁸Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
⁹Institut Paoli-Calmettes, Marseille, FRA
¹⁰Hematologie clinique, Institut Paoli Clamettes, Marseille, France

1995

Analysis of Multiplexed Single Cell RNA Sequencing Clinical Correlative Data in AML Reveals Biomarkers of Resistance

Charalambos Andreadis, MD¹, Tommy Jiang¹^*, Victoria Wang²^*, Ravi Patel, PhD³^*, Arjun Rao, PhD³^*, Chun Jimmie Ye, PhD⁴^* and Bradley W Blaser, MD, PhD⁵

¹Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA
²University of California (San Francisco), San Francisco, CA
³Data Science CoLab, University of California San Francisco, San Francisco, CA
⁴Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA
⁵The Ohio State University Comprehensive Cancer Center and Division of Hematology, Columbus, OH

1996

Genomic Analysis of Congenital Myeloid Sarcoma Identifies Significant Bone Marrow Involvement in the Absence of Morphologic Blasts

Jennifer Kamens, MD¹, Jinjun Dang, PhD¹^*, Sarah Aldridge, MSN²^*, Jing Ma, PhD³^*, Yuanyuan Wang, PhD²^*, Gang Wu, PhD⁴^*, Vasiliki Leventaki, MD⁵^*, Susana C. Raimondi, PhD³, Joy Nakitandwe, PhD³^*, Alberto Pappo, MD²^* and Tanja Gruber, MD, PhD¹^*

¹Department of Pediatrics, Stanford University, Palo Alto, CA
²Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN
³Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
⁴Center for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN
⁵Medical College of Wisconsin, Milwaukee, WI

1997

Prevalence of Inherited Predisposition Syndromes in Young Patients with Acute Myeloid Leukemia and Aberrant Karyotype

Martin Kirschner¹^*, Benjamin Rolles, MD²^*, Martina Crysandt²^*, Christoph Röllig, Prof., MD³^*, Friedrich Stolzel, MD³^*, Martin Bornhäuser, MD³^*, Carsten Müller-Tidow, MD⁴^*, Kim Kricheldorf²^*, Margherita Vieri, PhD²^*, Matthias Begemann⁵^*, Angela Maurer²^*, Jens Panse, MD², Susanne Isfort²^*, Marcin Wlodarski, MD, PhD^6,7, Sushree Sangita Sahoo, PhD⁸^*, Tim H Brümmendorf, MD², Edgar Jost²^* and Fabian Beier, MD²^*

¹Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, University Hospital Aachen, Aachn, Germany
²Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, University Hospital Aachen, Aachen, Germany
³Department of Hematology and Oncology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany
⁴Department of Internal Medicine V (Hematology/Oncology/Rheumatology), Heidelberg University Hospital, Heidelberg, Germany
⁵Institute of Human Genetics, Medical Faculty, RWTH Aachen University, Aachen, Germany
⁶Department of Hematology, St. Jude Children’s Research Hospital, Memphis, TN
⁷Department of Pediatrics and Adolescent Medicine, University Medical Center Freiburg, Freiburg, Germany
⁸Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg Im Breisgau, Germany

1998

Single-Cell Transcriptomic Profiling of De Novo and Relapsed Acute Myeloid Leukemia Identifies a Leukemic Stemness Program Shared across Diverse Phenotypes

Samantha Worme, BSc^1,2^*, Selin Jessa, BSc³^*, William Poon, BSc^1,2^*, Maja Jankovic, MSc^1,2^*, Gabriela Galicia Vazquez, PhD¹^*, Alexandre Bazinet, MD^2,4, Katharine Fooks, BSc^1,2^*, Isabella Iasenza, BSc^2,5, Patricia Arreba-Tutusaus, PhD⁵^*, Kolja Eppert, PhD^5,6, Ioannis Ragoussis, PhD^7,8^*, Yu Chang Wang, PhD⁷^*, Nathalie A Johnson, MD, PhD^2,4, Sarit E Assouline, MD, MSc^2,4, Claudia L Kleinman, PhD⁸^* and François E Mercier, MD^2,4^*

¹Lady Davis Institute for Medical Research, Montreal, QC, Canada
²Department of Medicine, McGill University, Montreal, QC, Canada
³Quantitative Life Sciences, McGill University, Montreal, QC, Canada
⁴Jewish General Hospital, Lady Davis Institute for Medical Research and Segal Cancer Centre, Montreal, QC, Canada
⁵Research Institute of the McGill University Health Centre, Montreal, QC, Canada
⁶Department of Pediatrics, McGill University, Montreal, QC, Canada
⁷McGill University Genome Centre, Montreal, QC, Canada
⁸Department of Human Genetics, McGill University, Montreal, QC, Canada

1999

Prognostic Impacts of Next-Generation Sequencing-Based Measurable Residual Disease Monitoring before and after Allogeneic Hematopoietic Cell Transplantation in AML

Byung Sik Cho, M.D., Ph.D.¹^*, Dain Kang²^*, Hoon Seok Kim²^*, Heeje Kim, MD, PhD³, Myungshin Kim, MD, PhD⁴^* and Yonggoo Kim⁴^*

¹Department of Hematology, Leukemia Research Institute, Seoul St. Mary’s Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
²Department of Laboratory Medicine, Catholic University of Korea, Seoul, Korea, Republic of (South)
³Department of Hematology, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Seoul, Korea, Republic of (South)
⁴Department of Laboratory Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Seoul, Korea, Republic of (South)

2000

Clonal Architecture and Variant Allele Frequency Predict Clinical Outcomes and Drug Response in Acute Myeloid Leukemia

Brooks Benard, BS^1,2^*, Logan Leak, BS^1,3^*, Armon Azizi, BS²^*, Daniel Thomas, MD, PhD⁴, Andrew Gentles, PhD⁵^* and Ravi Majeti²

¹Cancer Biology Program, Stanford University, Stanford, CA
²Department of Medicine, Division of Hematology, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA
³Department of Biology, Stanford Univerisity, Stanford, CA
⁴Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia
⁵Department of Biomedical Informatics, Stanford University School of Medicine, Stanford, CA

2001

TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia

Catherine Lai, MD, MPH¹, Jayakumar Vadakekolathu, PhD²^*, Stephen Reeder, BSc²^*, Sarah E. Church, PhD³^*, Carmen Ballesteros-Merino, PhD⁴^*, Ibrahim Aldoss, M.D.⁵, Anjali S Advani, MD⁶, John E. Godwin, MD⁷, Matthew J. Wieduwilt, MD, PhD⁸, Martha L. Arellano, MD⁹, Geoffrey L Uy, MD¹⁰, Farhad Ravandi, MBBS¹¹, Matthew C Foster, MD¹², Emmanuel Gyan, MD, PhD¹³, Patrick J. Stiff, MD¹⁴, Norbert Vey, MD¹⁵, Ashkan Emadi, M.D., Ph.D.¹⁶, Matteo Giovanni Carrabba, MD¹⁷^*, Roland B. Walter, MD, PhD, MS¹⁸, Peter H. Sayre, MD, PhD¹⁹, Kathy Tran²⁰^*, Erin Timmeny²¹^*, Michael P. Rettig, PhD²², Patrick Kaminker, PhD²⁰^*, John Muth, MS²⁰^*, Kuo Guo, MSc²³^*, Tung On Yau²^*, Peter J.M. Valk, PhD²⁴, Bob Lowenberg, MD, PhD²⁵, Ivana Gojo, MD²⁶, Martin Bornhäuser, MD²⁷^*, John F. DiPersio, MD²⁸, Jan K Davidson-Moncada, MD, PhD²⁰ and Sergio Rutella, MD, PhD, FRCPath^2,29

¹Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC
²John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom
³NanoString Technologies, Inc., Seattle, WA
⁴Providence Cancer Center, Earl A. Chiles Research Institute, Portland, OR
⁵Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA
⁶Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
⁷Providence Portland Medical Center, Portland, OR
⁸Moores Cancer Center, University of California, San Diego, La Jolla, CA
⁹Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
¹⁰Washington University School of Medicine, Saint Louis, MO
¹¹Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
¹²Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, Chapel Hill, NC
¹³Centre Hospitalier Universitaire, Service D'Hemaologie Et Therapie Cellulaire, Tours Cedex, France
¹⁴Loyola University Chicago Stritch School of Medicine, Maywood, IL
¹⁵Hematologie clinique, Institut Paoli Clamettes, Marseille, France
¹⁶University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
¹⁷Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
¹⁸Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
¹⁹University of California, San Francisco, San Francisco, CA
²⁰MacroGenics, Inc., Rockville, MD
²¹MacroGenics, Inc., ROCKVILLE, MD
²²Department of Internal Medicine, Division of Oncology, Washington Univ. School of Med., Saint Louis, MO
²³Macrogenics,Inc, ROCKVILLE, MD
²⁴Erasmus University Medical Center, Rotterdam, Netherlands
²⁵Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands
²⁶Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
²⁷Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany
²⁸Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO
²⁹Centre for Health, Ageing and Understanding Disease (CHAUD), Nottingham Trent University, Nottingham, United Kingdom

2002

Validation of the High-Risk Prognostic Score Defined By the Presence of Mutations in NRAS or TP53 in a Cohort of 497 Patients with Acute Myeloid Leukemia

Rosa Ayala, MD, PhD¹^*, Pau Montesinos, MD, PhD^2,3^*, Eva Barragán, PhD^4,5,6^*, Joaquin Martinez-Lopez, MD^7,8,9,10^*, Miguel A. Sanz^5,11,12, Yanira Ruiz-Heredia¹³^*, Santiago Barrio¹⁴^*, Juan Manuel de la Rosa¹³^*, Inmaculada Rapado¹⁵^*, Pilar Martinez, MD¹⁶^*, Rafael Colmenares¹⁷^*, Maria Pozas¹⁷^*, Xabier Gutierrez¹⁷^*, María Luz Morales¹⁸^* and Noemí Álvarez Sánchez-Redondo, PhD¹³^*

¹Hematology Department, Hospital Universitario 12 de Octubre,, Madrid, Spain
²CIBERONC, Instituto Carlos III, Madrid, Spain
³Hospital Universitari i Politècnic La Fe, Valencia, Spain
⁴Servicio de Hematología. Hospital La Fe, Valencia, Spain, Valencia, Spain
⁵CIBERONC, Madrid, Spain
⁶Hematology Department, Hospital Universitario La Fe de Valencia,, Valencia, Spain
⁷Hematology and hemotherapy department, Hospital Universitario 12 De Octubre, Madrid, Spain
⁸Hospital Universitario 12 de Octubre (H12O), Centro Nacional de Investigaciones Oncológicas (CNIO)-H12O and Universidad Complutense de Madrid, Madrid, Spain
⁹Hospital 12 de Octubre, H12O-CNIO, Haematological Malignancies Clinical Research Unit, Universidad Complutense, CIBERONC, Madrid, Spain
¹⁰H12O-CNIO Hematological Malignancies Clinical Research Unit, Spanish National Cancer Research Center, Madrid, Spain
¹¹Hematology Department, University and Polytechnic Hospital La Fe, Valencia, Spain
¹²Department of Medicine, University of Valencia, Valencia, Spain
¹³Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12) Hematological Tumors Clinical Research Unit H12O-CNIO, Madrid, Spain, Madrid, Spain
¹⁴Hospital 12 De Octubre, CIBERONC, Madrid, ESP
¹⁵Department of Hematology, Hospital Universitario 12 de Octubre, CNIO, Madrid, Spain
¹⁶Haematology department, 12 Octubre Hospital, Madrid, Spain
¹⁷) Department of Translational Hematology, Hematology Service, Hospital 12 de Octubre, Madrid, Spain, Madrid, Spain
¹⁸Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC, Madrid, Spain

2003

Target-Informed Repurposing of Immunotherapies in AML – a Transcriptome Based Approach for Identifying Immediately Available Therapeutics

Amanda R. Leonti, MS¹^*, Makia Manselle²^*, Jenny L. Smith, MSc, MEd²^*, Rhonda E. Ries, MA²^*, Anders E. Kolb, MD³ and Soheil Meshinchi, MD, PhD^4,5,6

¹Clinical Research Division, Fred Hutchinson Cancer Research Center, Mountlake Terrace, WA
²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
³Division of Oncology, Nemours/Alfed I. duPont Hospital For Children, Wilmington, DE
⁴Department of Pediatrics, University of Washington, Seattle, WA
⁵Clinical Research Division, Fred Hutchinson Cancer Rsrch. Ctr., Seattle, WA
⁶Children's Oncology Group, Monrovia, CA

2004

FLT3 Inhibitors Induce Instability of p53 By Mir-181 Mediated Downregulation of Deubiquitinase YOD1 in Acute Myeloid Leukemia

Han Zhong Pei¹^*, Yao Guo, PhD¹^*, Bo Lu, MD¹^*, Zhiguang Chang, PhD¹^*, Dengyang Zhang, PhD¹^*, Liuting Yu¹^*, Yuming Zhao¹^*, Suk-Hwan Baek, PhD²^*, Yun Chen, PhD¹^* and Zhizhuang Joe Zhao, PhD^1,3

¹The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China
²Yeungnam University, Daegu, Korea, Republic of (South)
³Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK

2005

Mitochondrial Spare Reserve Capacity : A New Predictive Metabolic Biomarker for Aggressiveness of Acute Myeloid Leukemia

Quentin Fovez¹^*, Bruno Quesnel, MD, PhD^1,2, William Laine¹^*, Raeeka Khamari¹^*, Celine Berthon, MD, PhD^1,2^*, Laure Goursaud, MD^1,2^*, Nicolas Germain, MD^1,3^*, Claude Preudhomme, MD, PhD^1,3, Philippe Marchetti, MD, PhD^1,3^* and Jérôme Kluza, PhD¹^*

¹UMR9020-U1277 - CANTHER, INSERM CNRS, LILLE, France
²Service des Maladies du Sang, Hôpital Huriez, Centre Hospitalier Universitaire de Lille, LILLE, France
³Centre de Biologie-Pathologie, CHU Lille, Lille, France

2006

Molecular and Clinical Aspects of Acute Myeloid Leukemia with Inv(3)(q21q26)/t(3;3)(q21;q26) Carrying Spliceosomal Mutations

Hassan Awada, MD¹, Cassandra M Kerr, MS²^*, Heesun J. Rogers, MD, PhD³, Jaroslaw P. Maciejewski, MD, PhD² and Valeria Visconte, PhD¹

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
³Department of Hematopathology, Cleveland Clinic, Cleveland

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH